Literature DB >> 34903873

Merck's COVID pill loses its lustre: what that means for the pandemic.

Max Kozlov.   

Abstract

Entities:  

Keywords:  Drug discovery; Public health; SARS-CoV-2

Year:  2021        PMID： 34903873     DOI： 10.1038/d41586-021-03667-0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.

Authors:  Marie O Pohl; Laura Martin-Sancho; Ranjala Ratnayake; Kris M White; Laura Riva; Qi-Yin Chen; Gauthier Lieber; Idoia Busnadiego; Xin Yin; Samuel Lin; Yuan Pu; Lars Pache; Romel Rosales; Marion Déjosez; Yiren Qin; Paul D De Jesus; Anne Beall; Sunnie Yoh; Benjamin G Hale; Thomas P Zwaka; Naoko Matsunaga; Adolfo García-Sastre; Silke Stertz; Sumit K Chanda; Hendrik Luesch
Journal:  ACS Infect Dis       Date:  2022-06-29       Impact factor: 5.578

2.  Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue.

Authors:  Zhonglei Wang; Liyan Yang
Journal:  Front Public Health       Date:  2022-06-17

Review 3.  Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective.

Authors:  J Carlos Menéndez
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

Review 4.  Inhibitors of SARS-CoV-2 PLpro.

Authors:  Dale J Calleja; Guillaume Lessene; David Komander
Journal:  Front Chem       Date:  2022-04-26       Impact factor: 5.545

5.  Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.

Authors:  Yuan Bai; Mingwang Shen; Lei Zhang
Journal:  Viruses       Date:  2022-04-06       Impact factor: 5.818

6.  SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.

Authors:  Carolin M Lieber; Robert M Cox; Julien Sourimant; Josef D Wolf; Kate Juergens; Quynh Phung; Manohar T Saindane; Meghan K Smith; Zachary M Sticher; Alexander A Kalykhalov; Michael G Natchus; George R Painter; Kaori Sakamoto; Alexander L Greninger; Richard K Plemper
Journal:  Nat Commun       Date:  2022-07-29       Impact factor: 17.694

Review 7.  Coagulopathy during COVID-19 infection: a brief review.

Authors:  Robin M Cunningham; Kyle L Johnson Moore; Jacen S Moore
Journal:  Clin Exp Med       Date:  2022-09-19       Impact factor: 5.057

Review 8.  Bioactive natural products in COVID-19 therapy.

Authors:  Zhonglei Wang; Ning Wang; Liyan Yang; Xian-Qing Song
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.